Characterization of clinical tolerance to inhaled zinc oxide in naive subjects and sheet metal workers.
Clinical tolerance to the acute effects of zinc oxide inhalation develops in workers during periods of repeated exposure. The aims of this study were to determine whether clinical tolerance is accompanied by a reduction in the acute pulmonary inflammatory and cytokine responses to zinc oxide exposure and whether tolerance can be demonstrated in sheet metal workers who chronically inhale low levels of zinc oxide. Naive (never-exposed) subjects inhaled 5 mg/m3 zinc oxide on 1 or 3 days and underwent bronchoalveolar lavage 20 hours after the final exposure. Sheet metal workers inhaled zinc oxide on 1 day and control furnace gas on another day. Among naive subjects in whom tolerance was induced, bronchoalveolar lavage fluid percent neutrophils and interleukin-6 (IL-6) levels were significantly decreased compared with subjects who underwent only a single exposure. Sheet metal workers were much less symptomatic, but they still experienced a significant increase in plasma IL-6. The results indicate that clinical tolerance to zinc oxide is accompanied by reduced pulmonary inflammation and that chronically exposed sheet metal workers are not clinically affected by exposure to zinc oxide fume at the Occupational Safety and Health Administration Permissible Exposure Limit. The increase in IL-6 levels observed in the clinically responsive, and to a lesser extent, tolerant, states following zinc oxide inhalation is consistent with the dual role of IL-6 as a pyrogen and anti-inflammatory agent.
Fine
J M
JM
Pulmonary and Critical Care Section, Norwalk Hospital, Conn. 06856, USA.
Gordon
T
T
Chen
L C
LC
Kinney
P
P
Falcone
G
G
Sparer
J
J
Beckett
W S
WS
D000280:Administration, Inhalation; D000328:Adult; D000704:Analysis of Variance; D001831:Body Temperature; D018893:Bronchoalveolar Lavage; D005260:Female; D006261:Headache; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008452:Maximum Allowable Concentration; D020714:Maximum Tolerated Dose; D008669:Metallurgy; D016273:Occupational Exposure / Q000009:adverse effects; D015034:Zinc Oxide / Q000008:administration & dosage* / Q000009:adverse effects
D015850:Interleukin-6; D015034:Zinc Oxide